Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A

Slides:

Advertisements

Similar presentations

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.

Advertisements

Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Diagnosis and Treatment of Hyponatremia

Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients Jiacong Luo, MD, MS, MPH, Donna E.

Peritoneal dialysis American Journal of Kidney Diseases

Gregory L. Hundemer, MD, MPH, Andrew Z. Fenves, MD, Kristy M

Regional Differences in the Associations Between Prescribed Dialysate Sodium Concentration and Interdialytic Weight Gain in the Dialysis Outcomes and.

Jessica W. Weiss, MD, Eric S. Johnson, PhD, Amanda Petrik, MS, David H

Surviving the First Year of Peritoneal Dialysis: Enduring Hard Times

Edmund J. Bini, MD, MPH, Aditi Kinkhabwala, MD, David S. Goldfarb, MD

A Decade After the KDOQI CKD Guidelines

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target Szu-Chun Hung, Der-Cherng Tarng Kidney International

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective J. Michael Lazarus, MD, Raymond M. Hakim,

Recognition for Conservative Care in Kidney Failure

Sevelamer Prescriptions After Reporting of the Dialysis Clinical Outcomes Revisited (DCOR) Trial Findings: An Analysis of 5,495 Patients Receiving Maintenance.

Evaluation of the Potential Living Kidney Donor

Volume 84, Issue 3, Pages (September 2013)

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

Hemodialysis Facility Variation in Hospitalization and Transfusions Using Medicare Claims: The DOPPS Practice Monitor for US Dialysis Care Douglas S.

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Wayne Trebbin, MD, Peter Monteleone, MD

Volume 70, Pages S21-S25 (December 2006)

The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle Douglas S. Fuller, MS, Ronald L. Pisoni,

Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns.

Hemoglobin Level and Transfusions in Patients on Maintenance Dialysis: Where the Rubber Meets the Road Eduardo Lacson, MD, MPH, Franklin Maddux, MD

Nosratola D. Vaziri, MD American Journal of Kidney Diseases

Iain C. Macdougall, MD American Journal of Kidney Diseases

David C. Mendelssohn, MD, FRCPC, Jay B. Wish, MD

On Statin Treatment to Prevent Sepsis in Dialysis Patients

Michael Copland, MD, Paul Komenda, MD, Eric D

Factors Influencing Route of Administration for Epoetin Treatment Among Hemodialysis Patients in the United States Mae Thamer, PhD, Yi Zhang, DDS, MS,

This Month in AJKD American Journal of Kidney Diseases

Usability Testing and Acceptance of an Electronic Medication Inquiry System for CKD Patients Clarissa J. Diamantidis, MD, MHS, Marni Zuckerman, MA, Wanda.

Quiz Page July 2012 American Journal of Kidney Diseases

Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study Wolfgang.

Use of Diuretics in Heart Failure: A Precarious Balance

Elevated Fibroblast Growth Factor 23 in a Patient With Metastatic Prostate Cancer and Hypophosphatemia Casey L. Cotant, MD, Panduranga S. Rao, MD, DNB,

Interdialytic Weight Gain: Trends, Predictors, and Associated Outcomes in the International Dialysis Outcomes and Practice Patterns Study (DOPPS) Michelle.

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP)

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Salicylate Intoxication as a Cause of Pseudohyperchloremia

The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder.

Quiz Page April 2008 American Journal of Kidney Diseases

Study Designs in Patient-Oriented Research

Drug Dose Adjustments in Patients With Renal Impairment

Erratum American Journal of Kidney Diseases

Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS

George L. Bakris, MD, John M. Burkart, MD, Eric D

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target American.

Risk for Incident Renal Dialysis in a Managed Care Population

Trial Quality in Nephrology: How Are We Measuring Up?

Multidrug-Resistant Organisms Within the Dialysis Population: A Potentially Preventable Perfect Storm David P. Calfee, MD, MS American Journal of Kidney.

Differences in Blood Transfusion Trends Between US and UK Centers

Erratum American Journal of Kidney Diseases

Ronald L. Pisoni, PhD, MS, Brenda W. Gillespie, PhD, David M

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

American Journal of Kidney Diseases

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.

Juan Jesús Carrero, PhD American Journal of Kidney Diseases

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

Dialysis Research and N-of-1 Trials: Made for Each Other?

Clinical Practice Recommendations For Peritoneal Dialysis Adequacy

A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Adam Whaley-Connell, DO, MSPH

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Quiz page December 2003 American Journal of Kidney Diseases

What Should a Guideline Panel Do When Evidence Is Inconclusive

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Medication Adherence Behavior and Priorities Among Older Adults With CKD: A Semistructured Interview Study Dena E. Rifkin, MD, MS, M. Barton Laws, PhD,

Presentation transcript:

The DOPPS Practice Monitor for US Dialysis Care: Trends Through December 2011 Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A. Bieber, MPH, MS, Brenda W. Gillespie, PhD, Bruce M. Robinson, MD, MS American Journal of Kidney Diseases Volume 61, Issue 2, Pages 342-346 (February 2013) DOI: 10.1053/j.ajkd.2012.10.002 Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Change in ESA (erythropoiesis-stimulating agent) and IV (intravenous) iron treatment practices from October 2010 to October 2011, by September hemoglobin level. ESA and IV iron use represent prescription during a 1-month period. Weekly IV epoetin doses are estimated using 1-month values among treated patients. Monthly IV iron doses are estimated using 3-month averages among treated patients. American Journal of Kidney Diseases 2013 61, 342-346DOI: (10.1053/j.ajkd.2012.10.002) Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Change in selected facility treatment targets from 2010 to 2011. Abbreviation: PTH, parathyroid hormone. Based on medical directors surveyed at 59 DOPPS US study sites (the DOPPS 4 Medical Director Survey, conducted September to November 2011). American Journal of Kidney Diseases 2013 61, 342-346DOI: (10.1053/j.ajkd.2012.10.002) Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Facility hemoglobin (Hb) threshold to start erythropoiesis-stimulating agent therapy in non–dialysis-dependent CKD and new dialysis patients. Based on the DOPPS 4 Medical Director Survey, conducted September to November 2011. American Journal of Kidney Diseases 2013 61, 342-346DOI: (10.1053/j.ajkd.2012.10.002) Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

Figure 4 Facility hemoglobin (Hb) threshold for administering blood transfusions, 2010 and 2011. Abbreviation: CAD, coronary artery disease. Based on the DOPPS 4 Medical Director Survey, conducted September to November 2011. American Journal of Kidney Diseases 2013 61, 342-346DOI: (10.1053/j.ajkd.2012.10.002) Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions